Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
80
datasets available to search
ShareScore release 0.9.0
Dataset results
80 results for “carbapenem resistance”
PubMLST allele profiles and sequence alignments of 382 carbapenem-resistant Pseudomonas aeruginosa isolates collected from Japanese hospitals in 2019-2020
<p>This dataset provides PubMLST allele profiles, sequence alignments, and Mash distance data used in the study of "Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan". </p>
Genome assemblies of 382 carbapenem-resistant Pseudomonas aeruginosa isolates collected from Japanese hospitals in 2019−2020
<p>This dataset provides genome assemblies used in the study of "Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan".</p> <p> </p>
Draft genomes of 972 carbapenem-resistant Pseudomonas aeruginosa isolates (shovill assemblies of Reyes et al 2023 dataset raw reads)
<p>This dataset contains shovill assemblies of raw reads released under NCBI BioProject PRJNA824880 generated in Reyes J et al (The Lancet Microbe. Volume 4 Issue 3 Pages e159-e170 (March 2023); DOI: 10.1016/S2666-5247(22)00329-9)</p> <p> </p>
Raw Data for the article: Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis
<p><strong>Background: </strong>Spontaneous bacterial peritonitis (SBP) is a severe and often fatal infection in patients with decompensated cirrhosis and ascites. The only cure for SBP is antibiotic therapy, but the emerging problem of bacterial resistance requires novel therapeutic strategies. Human amniotic mesenchymal stromal cells (hA-MSCs) possess immunomodulatory and anti-inflammatory properties that can be harnessed as a therapy in such a context.</p> <p><strong>Methods: </strong>An in vitro applications of hA-MSCs in ascitic fluid (AF) of cirrhotic patients, subsequently infected with carbapenem-resistant Enterobacterales, was performed. We evaluated the effects of hA-MSCs on bacterial load, innate immunity factors, and macrophage phenotypic expression.</p> <p><strong>Results: </strong>hA-MSCs added to AF significantly reduce the proliferation of both bacterial strains at 24 h and diversely affect M1 and M2 polarization, C3a complement protein, and ficolin 3 concentrations during the course of infection, in a bacterial strain-dependent fashion.</p> <p><strong>Conclusion: </strong>This study shows the potential usefulness of hA-MSC in treating ascites infected with carbapenem-resistant bacteria and lays the foundation to further investigate antibacterial and anti-inflammatory roles of hA-MSC in in vivo models.</p>
Recurrent Campylobacter jejuni infections with in vivo selection of resistance to macrolides and carbapenems – assembly dataset
<p><strong>Dataset</strong></p> <p>This dataset comprises the genome assemblies of the first isolate collected from each clinical case (A1 and B1), together with the respective annotation.</p> <p>File “Cje_metadata.xlsx” contains the genome assembly statistics for each isolate, including the European Nucleotide Archive (ENA) accession numbers, genotyping and antibiotic resistance profiles.</p> <p>The directory “Assemblies/” contains the genome assembly (.fasta and .gbk formats) of each isolate presented in the metadata file.</p> <p> </p> <p><strong>Genome assembly and annotation</strong></p> <p>Reads quality control and improvement, species confirmation (using the 8GB database available at https://ccb.jhu.edu/software/kraken/) and <em>de novo</em> assembly were performed using the INNUca v4.2.2 pipeline (https://github.com/B-UMMI/INNUca). Briefly, after reads’ quality analysis using FastQC v0.11.5 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and cleaning with Trimmomatic v0.38 (http://www.usadellab.org/cms/?page=trimmomatic), genomes were <em>de novo</em> assembled with SPAdes 3.14.0 (http://bioinf.spbau.ru/spades) with a mean depth of coverage above 160x, and subsequently improved using Pilon v1.23. Multi-Locus Sequence Typing (MLST) was performed using mlst v2.18.1 software (https://github.com/tseemann/mlst). Genome annotation was performed with RAST server v2.0 (http://rast.nmpdr.org/).</p> <p>The raw sequence reads of each isolate were deposited at ENA under the study accession numbers PRJEB42628 and PRJNA505131.</p> <p> </p> <p><strong>Funding</strong></p> <p>This work was supported by GenomePT (ref. POCI-01-0145-FEDER-022184) from Fundação para a Ciência e Tecnologia, Portugal.</p>
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
ClinicalTrials.gov study NCT02714595. IPD Sharing: Not stated. Countries: 16. Publications: 5.
Polyphasic characterization of carbapenem-resistant Klebsiella pneumoniae clinical isolates suggests vertical transmission of the blaKPC-3 gene
<p>Optical DNA mapping (ODM) data related to the study, presented in figures 2-6 in the paper.</p>
IMPACT OF TEBIPENEM-PIVOXIL ON THE INTESTINAL MICROBIOTA AND ON ESTABLISHMENT OF COLONIZATION WITH CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE IN MICE
<p><span>Antimicrobial therapy has the</span><span> potential to cause unintended adverse effects by promoting antibiotic-resistant bacteria. Therefore, as new antibiotics are developed there is a need to understand their potential to disrupt the indigenous microbiota of the colon and promote colonization by pathogens. Tebipenem pivoxil (Teb-piv), the first oral carbapenem, has potent <em>in vitro</em> activity against <em>Enterobacterales</em> pathogens, but requires combination with an appropriate β-lactamase inhibitor to achieve activity against <em>Klebsiella pneumoniae</em> carbapenemase and metallo-β-lactamase (MBL)-producing carbapenem-resistant <em>Enterobacterales</em></span></p>
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
ClinicalTrials.gov study NCT01041716. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs
ClinicalTrials.gov study NCT05985057. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
ClinicalTrials.gov study NCT04759001. IPD Sharing: YES. Countries: 1. Publications: 5.
Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
ClinicalTrials.gov study NCT05002582. IPD Sharing: NO. Countries: 1. Publications: 2.
Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia
ClinicalTrials.gov study NCT00722410. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
ClinicalTrials.gov study NCT05586815. IPD Sharing: NO. Countries: 1. Publications: 2.
Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia
ClinicalTrials.gov study NCT03597841. IPD Sharing: Not stated. Countries: 1. Publications: 22.
Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae
ClinicalTrials.gov study NCT00753558. IPD Sharing: Not stated. Countries: 1. Publications: 7.
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
ClinicalTrials.gov study NCT02709408. IPD Sharing: YES. Countries: 11. Publications: 25.
Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments
ClinicalTrials.gov study NCT01703299. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
ClinicalTrials.gov study NCT06051513. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.